Skip to content
Bamboo Works
Search
Register / Sign in
MSCI China | MSCI China Small-Cap | Hang Seng Index | Hang Seng China Enterprise
  • Categories
    • IPO
    • Ecommerce
    • Finance
    • Social Media/Entertainment
    • Consumer
    • Education
    • Healthcare/biotech
    • New Energy
    • AI/Infrastructure/Resources
    • Property
  • Fast News
  • Expert Corner
  • Audio/Video
  • China ESG
  • About
    • Who We Are
    • Our Writers
    • Partner with us
    • Contact Us
    • Join us
  • Eng
  • 简中
  • 繁中
Menu
  • Categories
    • IPO
    • Ecommerce
    • Finance
    • Social Media/Entertainment
    • Consumer
    • Education
    • Healthcare/biotech
    • New Energy
    • AI/Infrastructure/Resources
    • Property
  • Fast News
  • Expert Corner
  • Audio/Video
  • China ESG
  • About
    • Who We Are
    • Our Writers
    • Partner with us
    • Contact Us
    • Join us

Healthcare/biotech

3SBio hits the big time with $6 billion cancer drug deal

3SBio hits the big time with $6 billion cancer drug deal

The pharma giant Pfizer has bought international rights to the experimental cancer therapy and will take a $100 million equity stake in the Chinese drug developer Key Takeaways: The mega…
May 29, 2025
1530.HK
Will Trump’s drug order derail China’s overseas pharma push?

Will Trump’s drug order put the brakes on China’s overseas pharma drive?

The U.S. president has promised to reduce prescription drug prices by 30% to 80% for Americans, insisting they are entitled to prices paid in other developed countries Key Takeaways: Pharma…
May 22, 2025
Estenova aims to become a big name in medical aesthetics

Estenova aims to become a big name in medical aesthetics

The Chinese developer of anti-wrinkle fillers is seeking a cash injection from a Hong Kong share listing to bring its plumping products to the market Key Takeaways: The biotech made…
May 16, 2025
Kintor makes Koshine, a hair loss product

Kintor Pharma shifts from cancer drugs to cosmetics as funds run low

The cash-strapped biotech has begun generating its first revenue from over-the-counter cosmetic treatments, as it pivots away from its original oncology drugs Key Takeaways: Kintor Pharma is shifting from its…
May 15, 2025
9939.HK
BeiGene celebrates profit milestone

BeiGene celebrates profit milestone on soaring drug sales

Buoyed by U.S. demand for its blockbuster cancer drug, the Chinese biopharma firm has delivered its first quarterly profit on a GAAP basis Key Takeaways: Global sales of the company’s…
May 15, 2025
6160.HK ONC.US 688325.SHG
Ribo Life has filed for a Hong Kong IPO

RNA drug developer Ribo Life targets fresh funding channel

The biopharma firm has filed for a Hong Kong IPO after already completing eight financing rounds to support its research into cutting-edge nucleotide drugs Key Takeaways: As a pioneer in…
May 8, 2025
Anti-toxin provider Jiangxi Institute joins biopharma IPO rush

Anti-toxin provider Jiangxi Institute joins biopharma IPO rush

The company enjoys a big share of China’s anti-tetanus market but is looking to diversify into antidotes for rabies and snake bites to drive future growth  Key Takeaways: The company…
April 24, 2025
Load more

Recent Articles

Newtrend set to make IPO
May 30, 2025

BRIEF: Newtrend launches Hong Kong IPO to raise up to $31 million

May 30, 2025

Cango’s crypto makeover advances with sale of its China business

CANG.US
May 30, 2025

AI powers Agora back to revenue growth

API.US
May 30, 2025

BRIEF: Shouhui slumps in Hong Kong trading debut

2621.HK
May 30, 2025

BRIEF: Futu’s profit doubles on stock market rebound

FUTU.US
May 30, 2025

WeRide tries buyback maneuver in tight robotaxi race

WRD.US
May 29, 2025

BRIEF: Shein abandons London listing plan, heads to Hong Kong

RELATED ARTICLES

  1. Earnings blow for CSPC Pharma
    March 6, 2025
    Earnings blow for CSPC Pharma as the state drives a hard bargain
    1093.HK
  2. January 9, 2025
    Cancer drug maker Genfleet joins Hong Kong IPO influx
  3. March 20, 2025
    A blockbuster cancer drug? TYK’s claims go under the microscope
    2410.HK
  4. April 10, 2025
    Investors cheer Akeso’s revenue milestone, even as it returns to the red
    9926.HK
  5. May 22, 2025
    Will Trump’s drug order put the brakes on China’s overseas pharma drive?
  6. February 6, 2025
    After a failed Fosun buyout, what’s next for drug maker Henlius Biotech?
    2696.HK
  7. March 13, 2025
    No respite for RemeGen as problems and losses pile up
    9995.HK 688331.SHG
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva

China stock insights and analysis for global investors: Bamboo Works unlocks investment opportunities in Chinese companies listed in the U.S. & Hong Kong.

  • About Us
  • Fast News
  • Audio/Video
  • Expert Corner
  • China ESG
Facebook Twitter Linkedin Weixin Weibo Youtube

Categories

  • New Energy
  • IPO
  • AI/Infrastructure/Resources
  • Education
  • Finance
  • Social Media/Entertainment
  • Consumer
  • Ecommerce
  • Healthcare/biotech
  • Property

Newsletter

Discover hidden China stock gems in our weekly newsletter
Copyright © 2021 - 2025 Bamboo Works. All rights reserved.